Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries.
Kim LauperDenis MonginFlorenzo IannoneEirik Klami KristianslundTore K KvienDan NordströmKarel PavelkaManuel Pombo-SuarezZiga RotarMaria Jose SantosCatalin CodreanuGalina LukinaDelphine S CourvoisierCem GabayPublished in: RMD open (2018)
With similar retention and effectiveness, TCZ-SC is an adequate alternative to TCZ-IV for RA. When possible, considering the costs of the TCZ-IV route, TCZ-SC should be the preferred mode of administration.